The dexlansoprazole capsules are the generic version of Takeda’s Dexilant.
As per the agreement, Par made a payment to Handa for the ANDA, giving it the exclusive rights to market, sell and distribute dexlansoprazole capsules in the US under the ANDA, subject to final FDA approval.
Par is eligible to receive a percentage of profits from the sales of the product.
Handa is currently involved in patent litigation concerning dexlansoprazole in the US District Court for the District of Northern California. Par will assume control of ongoing litigation.